71. Leveraging advances in biological understanding to inform combination decision-making. Issue 1 (2020) Authors: QUIGLEY, MICHAEL Journal: Immuno-oncology insights Issue: Volume 1:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
72. Leveraging LAG-3 for improved patient outcomes. Issue 1 (2022) Journal: Immuno-oncology insights Issue: Volume 3:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
73. Leveraging the advantages of liquid biopsy for predictive and prognostic biomarkers in R&D. Issue 3 (2021) Authors: Punyadeera, Associate Professor Chamindie Journal: Immuno-oncology insights Issue: Volume 2:Issue 3(2021) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
74. Leveraging the power for genomics for immuno-oncology. Issue 1 (2021) Journal: Immuno-oncology insights Issue: Volume 2:Issue 1(2021) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
75. Looking for the bigger picture: current challenges & progress in preclinical tools for I–O. Issue 1 (2023) Authors: McGuigan, Róisin; Candarlioglu, Pelin Journal: Immuno-oncology insights Issue: Volume 4:Issue 1(2023) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
76. Model-based dose escalation designs used in early-phase 1 trials to assess safety and tolerability of immuno-oncology therapies. Issue 3 (2020) Authors: Adessi, Céline; Michielin, Francesca Journal: Immuno-oncology insights Issue: Volume 1:Issue 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
77. Modelling the I-O manufacturing facilities of tomorrow. Issue 2 (2021) Authors: Lunger, John Journal: Immuno-oncology insights Issue: Volume 2:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
78. Modulation of both tumor & T cell apoptosis to enhance CAR-T immunotherapy. Issue 9 (2022) Authors: Ruella, Marco Journal: Immuno-oncology insights Issue: Volume 3:Issue 9(2022) Page Start: 527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
79. Necessity for next-generation quality assessment of CAR T cell manufacturing and advanced therapy guidance. Issue 3 (2020) Authors: Seliger, Barbara; Reiche, Kristin; Massa, Chiara; Fricke, Stephan Journal: Immuno-oncology insights Issue: Volume 1:Issue 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
80. Neoantigen vaccines for cancer: ready for primetime. Issue 2 (2020) Authors: Perales-Puchalt, Alfredo; Cooch, Neil; Shende, Ashwini; Sardesai, Niranjan Y Journal: Immuno-oncology insights Issue: Volume 1:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗